Estimating the Cost of Nosocomial Candidemia in the United States
Open Access
- 1 April 2001
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (7), 1110
- https://doi.org/10.1086/319613
Abstract
Sir—Candida species are the fourth most common cause of bloodstream infections in the United States [1] and are associated with an attributable mortality of up to 38% [2]. Recent estimates published in this journal suggest that each case of nosocomial candidemia results in excess costs of $34,123 per Medicare patient and $44,536 per private insurance patient, with national costs of nosocomial candidemia exceeding $200 million per year in the United States [3]. However, since that report was generated, our understanding of the epidemiology of nosocomial candidemia has significantly improved.Keywords
This publication has 5 references indexed in Scilit:
- The Epidemiology of Candidemia in Two United States Cities: Results of a Population-Based Active SurveillanceClinical Infectious Diseases, 1999
- Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year AnalysisClinical Infectious Diseases, 1999
- Accuracy of ICD-9-CM Codes in Detecting Community-acquired Pneumococcal Pneumonia for Incidence and Vaccine Efficacy StudiesAmerican Journal of Epidemiology, 1999
- The Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of IllnessClinical Infectious Diseases, 1998
- Hospital-Acquired CandidemiaArchives of Internal Medicine, 1988